Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

Fletcher's restructuring, impairment costs could hit $781m
Infrastructure

Fletcher's restructuring, impairment costs could hit $781m

It expects ebit of $370m to $375m before significant items. 

Selling Kiwifruit at Beijing’s $5b-a-year department store
Primary Sector

Selling Kiwifruit at Beijing’s $5b-a-year department store

Turns out the personal touch helps sell kiwifruit at a high-end Chinese supermarket.

Tait wants Vital to fast-track growth
Markets

Tait wants Vital to fast-track growth

If successful, Tait Communications will pay $18.7m to take the listed firm private.

NZX down 0.3% as world waits for Iranian response
Markets Market Close

NZX down 0.3% as world waits for Iranian response

"The inclination is not to do too much," Forsyth Barr analyst Peter Sigley said.

Gregor Thompson 23 Jun 2025